Rhino-Conjunctivitis - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Rhino-Conjunctivitis - Pipeline Review, H1 2016

Rhino-Conjunctivitis - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Rhino-Conjunctivitis - Pipeline Review, H1 2016
Published Jun 15, 2016
90 pages — Published Jun 15, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Rhino-Conjunctivitis - Pipeline Review, H1 2016, provides an overview of the Rhino-Conjunctivitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis
- The report reviews pipeline therapeutics for Rhino-Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Rhino-Conjunctivitis therapeutics and enlists all their major and minor projects
- The report assesses Rhino-Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Rhino-Conjunctivitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Rhino-Conjunctivitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rhino-Conjunctivitis pipeline

  
Source:
Document ID
GMDHC8178IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Rhino-Conjunctivitis Overview91
Therapeutics Development101
  Pipeline Products for Rhino-Conjunctivitis Overview101
Rhino-Conjunctivitis Therapeutics under Development by Companies111
Rhino-Conjunctivitis Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Rhino-Conjunctivitis Products under Development by Companies152
Rhino-Conjunctivitis Companies Involved in Therapeutics Development1713
  ALK-Abello A/S171
  Allergy Therapeutics Plc181
  ASIT biotech s.a.191
  Bial - Portela &Ca, S.A.201
  Circassia Pharmaceuticals Plc211
  Faes Farma, S.A.221
  Griffin Discoveries BV231
  HAL Allergy BV241
  Immunomic Therapeutics, Inc.251
  Laboratorios LETI S.L.261
  Oxagen Limited271
  Roxall Medizin GmbH281
  Stallergenes SAS291
Rhino-Conjunctivitis Therapeutics Assessment3010
  Assessment by Monotherapy Products301
  Assessment by Combination Products311
  Assessment by Target322
  Assessment by Mechanism of Action342
  Assessment by Route of Administration362
  Assessment by Molecule Type382
Drug Profiles4040
  Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis Drug Profile401
  Allergen for Allergic Rhinitis and Rhinoconjunctivitis Drug Profile411
  Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma Drug Profile421
  Allergen for Allergic Rhino-Conjunctivitis Drug Profile432
  Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis Drug Profile451
  Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis Drug Profile461
  Allergen for Cupressus Arizonica Pollen Induced Allergic Rhino-Conjunctivitis Drug Profile471
  Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis Drug Profile481
  Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis Drug Profile491
  Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis Drug Profile501
  Allergen for Salsola Kali Pollen Induced Allergic Rhinoconjunctivitis Drug Profile511
  Allergovac Drug Profile521
  ASP-4070 Drug Profile533
  bilastine Drug Profile562
  clustoid wiesenlieschgras Drug Profile581
  gp-ASIT Drug Profile592
  OC-000459 Drug Profile613
  OC-2417 Drug Profile641
  Pollinex Quattro Grass Drug Profile653
  Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma Drug Profile681
  standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine Drug Profile695
  Vaccine for Asthma and Ragweed-Induced Rhinoconjunctivitis Drug Profile742
  Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma Drug Profile762
  Vaccine for House Dust Mite Induced Allergic Rhinoconjunctivitis Drug Profile782
Rhino-Conjunctivitis Dormant Projects801
Rhino-Conjunctivitis Discontinued Products811
Rhino-Conjunctivitis Product Development Milestones827
  Featured News &Press Releases821
    Jun 13, 2014: Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study821
    Jun 09, 2014: ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen831
    May 18, 2014: BioTech Tools will be present at the EAACI congress841
    Mar 10, 2014: GREER Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) for Short Ragweed Allergies Phase III Data Published in Journal of Allergy and Clinical Immunology851
    Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics861
    Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites871
    Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA871
    Oct 31, 2011: HAL Allergy Includes First Patient In Phase II PURETHAL Mites Study881
Appendix892
  Methodology891
  Coverage891
  Secondary Research891
  Primary Research891
  Expert Panel Validation891
  Contact Us891
  Disclaimer901

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Rhino-Conjunctivitis - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Rhino-Conjunctivitis-Pipeline-Review-H1-2016-2088-15946>
  
APA:
Global Markets Direct - Market Research. (2016). Rhino-Conjunctivitis - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Rhino-Conjunctivitis-Pipeline-Review-H1-2016-2088-15946>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.